Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...

F RIDAY, Oct. 4, 2024 (HealthDay News) -- For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has ...

Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The US approval of Eli Lilly’s Ebglyss (lebrikizumab) in September 2024 places the company in a competitive position in the atopic dermatitis (AD) market. AD, also known as eczema, is a chronic ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

Eczema sufferers could soon find relief from a monthly jab that banishes the uncomfortable symptoms. Studies show four out of five people with the skin condition who take lebrikizumab will see ...

and lebrikizumab “will remain the treatment of choice for the immediate future due to prescriber familiarity and good efficacy data.” However, for patients who are unsuitable for IL-13 ...

Medscape Medical News, September 30, 2024 EADV 2024 Atopic Dermatitis Control on Biologic Persists Over 3 Years In a 3-year extension of the pivotal trials that provided lebrikizumab with an ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $100 from $81 and keeps a Buy rating on the shares. Eli Lilly (LLY) ...